Over recent years, PCI Pharma Services has made a focused and continued investment in growing its sterile fill-finish capabilities to support the growing demand for complex injectable therapies. This includes the addition of a new, large scale isolator fill-finish and lyophilization line at its Bedford, NH campus, alongside the strategic acquisition of Ajinomoto Althea in 2025, strengthening the company’s U.S. manufacturing imprint and technical expertise.

Further backed by significant investment from Bain Capital, Kohlberg, Mubadala and Partners Group, PCI is speeding up the expansion of its global sterile manufacturing network. In this Pharma Matters Q&A, Anshul Gupte, PhD, RAC Drugs, Vice President of Pharmaceutical Development at PCI Pharma Services, provides updates on the expansions in Bedford and León, Spain, and talks about the importance and advantages of being able to offer services across multiple modalities.

Contract Pharma: You are making investments at your sterile manufacturing sites in both the U.S. and Spain. What’s the importance of growing your footprints on both sides of the Atlantic, and what trends are driving that?

Anshul Gupte: PCI is growing its pharmaceutical development capabilities at its sterile manufacturing campuses in Bedford and León to include a dedicated Pharmaceutical Development Center of Excellence (CoE) at each location. The $11 million investment enhances our capabilities across various aspects of drug development. These range from first in human, early phase studies through…